News

imaware acquires binx health’s consumer testing business

The RMI group has completed sertain projects

The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.

NovaMedica LLC capital consolidation

The RMI Group consolidated a 100% stake in the capital of NovaMedica LLC, a Russian specialty pharma company

A RMI portfolio company sucessfully went for an IPO

Atea Pharmaceuticals, Inc., a RMI portfolio company, went for a $300 mln IPO at NASDAQ on October 30, 2020

07 March 2018

NovaMedica, a portfolio company of RMI, has concluded the biggest SPIC for creation of a greenfield pharmaceutical manufacturing facility in the pharmaceutical industry

Russian pharmaceutical company NovaMedica (a RMI portfolio company), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, Director General of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region. During its implementation NovaMedica will invest more than three billion Rubles in the creation of the facility. Today this SPIC is the biggest one in the Russian pharmaceutical industry in terms of the amount of investments.   

07 February 2018

NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies

Russian pharmaceutical company NovaMedica (a RMI company) announces start of its cooperation in the area of transfer of knowledge and technologies between the R&D Center of NovaMedica Innotech and the German company Evonik – one of the leading companies in the international market of excipients manufacturing for the pharmaceutical industry. This partnership will result into creation of a training facility for transfer of competences in the area of pharmaceutical technologies at the premises of NovaMedica Innotech in Russia.

26 December 2017

R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation

Russian pharmaceutical company NovaMedica, investment project of RMI, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements. 

22 December 2017

Interdepartmental Commission has approved NovaMedica’s application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility

Russian pharmaceutical company NovaMedica (investment project of RMI) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility. 

11 August 2017

NovaMedica appoints Rustam Iksanov as R&D Vice President

Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.

30 May 2017

NovaMedica began construction of a pharmaceutical plant in the Kaluga region

Russian pharmaceutical company NovaMedica, a portfolio company of RMI, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.